NLS Pharmaceutics AG (NLSPW) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Zurich, Switzerland. Le PDG actuel est Alexander Zwyer.
NLSPW a date d'introduction en bourse 2021-01-29, 3 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $7.43K.
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
